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Abstract   
 
Background:  
Cancer is the second leading cause of death overall in the United 
States yet accounts for most cases of pre-mature mortality in those 
younger than 85 years of age. Chemotherapy acts as one of the major 
treatment options. Unfortunately, the toxic properties of chemotherapy 
are not limited solely to neoplastic tissue and the quest for cancer 
reduction or elimination often leads to serious side effects. However, 
preliminary research has demonstrated that cycles of short-term 
fasting (STF) promote selective toxicity of cancer cells while protecting 
normal, healthy cells from chemotoxic damage, suggesting the 
practice may be a promising adjunct to human chemotherapy. Yet, is 
fasting safe, efficacious and tolerable? In order to explore the potential 
of fasting as an adjunct to cancer treatment, we must first ask: can 
periodic fasting alter toxicity profiles in cancer patients undergoing 
chemotherapy? 
 
Methods:   
 
A thorough and time-consuming search of MEDLINE-Pubmed, CINAHL, 
Clinical key, Web of Science and Google scholar using the terms 
fasting, cancer and chemotherapy. The studies were assessed using 
GRADE criteria. 
 
 
Results:   
 
The search revealed 386 articles of which 2 studies met exclusion 
criteria and addressed the clinical question. Fasting prior to 
chemotherapy significantly reduced both signs (hematologic) and 
symptoms (fatigue, nausea, vomiting, abdominal cramps, and 
weakness) of toxicity associated with chemical cancer treatment.  
 
Conclusion:   
 
Current research suggests that fasting during cancer therapy is safe 
and may help protect against chemotoxicity, implying the practice 
could conceivably be employed as an adjunct to chemotherapy.    
The major limitation of this review lies in the sparseness of human 
trials that focus on fasting and chemotherapy. Of these studies only 
one is a randomized controlled trial (pilot), the sample size for each 
 3 
study is small with a relatively homogenous participant population 
(women >60yro with breast cancer). Also, the number of hours spent 
fasting was different between the trials. More research is necessary 
with larger, more diverse sample sizes. 
 
Keywords:  Short-term fasting, chemotherapy, neoplasm  
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The Effect of Fasting on Toxicity Profiles 
of Patients Undergoing Chemotherapy 
 
Background 
Cancer is the second leading cause of death overall in the United 
States and accounts for most cases of pre-mature mortality in those 
younger than 85 years of age.1 According to the US National Cancer 
Institute’s Surveillance Epidemiology and End Results (SEER) 
Database, the individual lifetime risk of developing some form of 
cancer is 1 in 2 for men and 1 in 3 for women.2 Although heart disease 
is a more prolific arbiter of death, cardiovascular treatment has 
advanced to such a degree that North America has seen a 45% 
reduction in cardiovascular mortality within the past 66 years.1 By 
contrast, cancer mortality rates increased between 1950-1990 and 
although cancer related death has decreased from 1990-2010, this has 
been marginal in comparison to cardiovascular statistics (a reduction 
of 21%  for men and 12.6% for women).1,3  
Traditional oncological care relies on one of three modalities, 
alone or in conjunction: surgery, radiation and/or chemotherapy.4 
Chemotherapy acts as one of the major treatment options and has 
enhanced the efficacy of medical management since 1950.5 The 
standard for chemotherapeutic treatment utilizes medication designed 
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with direct toxic effect on neoplastic cells. Unfortunately, the toxic 
properties of chemotherapy are not limited solely to neoplastic tissue 
and the quest for cancer reduction or elimination often leads to serious 
consequences such as alteration of the normal hematologic profile, 
nausea & vomiting, fatigue, weakness, hair loss, headaches, 
gastrointestinal discomfort, peripheral neuropathy and even death.6 
The ability to develop and employ pharmacological agents that 
differentially target cancerous tissue has long vexed the research and 
medical community. However, recent research5 has demonstrated that 
cycles of short-term fasting (STF) promote selective toxicity of cancer 
cells while protecting normal, healthy cells from chemotoxic damage.  
The ability of STF to render cancer cells vulnerable to 
pharmacological agents is known as differential stress resistance 
(DSR).7,8  Research utilizing in-vitro and mouse models have 
demonstrated that under conditions of nutrient deprivation, normal 
cells are capable of reorganizing molecular function to support 
maintenance and repair activities--a relative quiescence. By nature of 
oncogenic alteration, cancer cells do not respond to anti-growth 
signals and it is believed that unchecked division in absence of 
nutritional support leads to an accumulation of reactive oxygen species 
(ROS) with subsequent apoptosis and vulnerability to chemotherapy.5-8 
Since damage to healthy cells (with subsequent side-effects) limits the 
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length and dose of medication used in cancer therapy, STF’s potential 
to protect against chemotherapy’s harmful effects may act as a 
promising adjunct to standard treatment.  
Indeed, animal studies that have operated under this premise 
have demonstrated enhanced medical efficacy of a number of 
chemotherapy drugs, allowing for cancer cell sensitization5 as well as 
the ability to increase medication dose while limiting detrimental 
biological consequences.8  Could these promising results from non-
human studies be translated into applicable clinical practice?  That is, 
could STF be integrated within cancer therapy in a safe and tolerable 
manner? The need for better cancer treatment, specifically where 
chemotherapy has become a main course of therapy for cancer 
treatment, brings this question into review. 
 
Methods 
A thorough search of MEDLINE-Pubmed, CINAHL, Clinical key, 
Web of Science and Google scholar using the terms fasting, cancer and 
chemotherapy. Studies were included if they were conduct on humans 
and published in English in the last 5 years. Articles were then 
appraised according to the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) Working Group guidelines.(cite 
the working group website, can be copied directly from an example 
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paper) 
 
Results 
 A systematic search for relevant literature revealed 386 results. 
Screening of these titles and abstracts led to an exclusion of 380 
studies due to duplication and/or irrelevance. Of the 6 remaining 
articles, 4 were rejected for their inability to meet eligibility criteria. 
The two articles kept for review include a case series report9 and a 
randomized pilot study.10 A quality summary of these articles can be 
found in Table 1: Quality Assessment of Reviewed Studies. 
Safdie et al (2009) 
 In this case series report,9 10 patients with heterogeneous 
cancer diagnoses were given the option of fasting prior to and/or after 
receiving chemotherapeutic agents during the period of April 2008 to 
August 2009. The 10 patients who volunteered for this investigation 
chose to fast for at least 1 cycle of chemotherapy with a minimum of 
48 hours (and up to 140 hours) prior to treatment and/or 5-56 hours 
after medication administration. The main intent of this study was to 
collect information regarding chemo-toxicity both with and without 
fasting; information from this was provided to help determine 
feasibility of randomized controlled trials utilizing STF.9  
 Patients were recruited for observation from a variety of 
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oncology clinics across the United States. The only eligibility criterion 
required to participate was the willingness to include STF within their 
standard chemotherapy treatment(s) at least 48 hours prior to 
medication administration.  Ten patients volunteered to employ STF--7 
women and 3 men with varying diagnoses, including 4 patients with 
breast cancer, 2 with prostate cancer and 1 patient each with, uterine, 
esophageal, ovary, or lung (non-small cell carcinoma) cancer. Some 
patients chose to fast beyond 48 hours before chemotherapy (up to 
140 hours) and all 10 participants fasted after receiving medication for 
at least 1 cycle of chemo. As this was a case series report rather than 
a randomized control trial, blinding was not possible; patients 
volunteered to fast and were fully cognizant of this choice. Eight of the 
10 patients fasted during some but not all cycles of chemotherapy, and 
were thus able to act as their own controls.9  
 To assess the potential impact of fasting on side-effect profiles, 
patients were provided a self-assessment survey that contained 16 
common side effects associated with chemotherapy. This survey was 
developed as a guide by Safdie and collegues using the Common 
Terminology Criteria for Adverse Events of the National Cancer 
Institute version 3.0. Self-reported side effects were graded from 0-4, 
0 being no side effect and 4 representing “severe.” These adverse 
experiences were further subdivided into “gastrointestinal, nervous 
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system and general” categories.  It is known that chemotherapy exerts 
cumulative effects. That is, as the number of chemotherapy cycles 
increases, so too does the potential for associated adverse effects; to 
account for this phenomenon, researchers within this study assessed 
data serially (see Figure 1). All patients reported a decrease in severity 
of chemotherapy side effects when undergoing STF during treatment. 
Although only reduction of fatigue and weakness were statistically 
significant, it should be noted that vomiting, abdominal cramps, 
diarrhea and mucositis were nearly nonexistent during the STF cycles.9    
  
De Groot et al (2015)  
 This randomized pilot study10 aimed to determine if STF could be 
safe, tolerable and efficacious when undertaken during chemotherapy 
for HER-2 negative breast cancer. In particular, de Groot and 
colleagues were interested in what effect STF may have on toxicity 
profiles in the form of undesirable side effects and hematologic 
function.  To determine this, 13 women with stage II or III HER-2 
negative breast cancer were recruited for observation. Inclusion 
criteria required that these women were to undergo TAC (docetaxel, 
doxorubicin and cyclophosphamide) treatment, were above the age of 
18, had a life expectancy > 3 months, had no prior diagnosis of 
diabetes mellitus, were not pregnant or nursing and began with 
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adequate cardiac, liver, kidney and bone marrow function.10 
 Subjects were randomly assigned into 1 of 2 groups. After blind 
allocation 7 patients were designated to fast for 24 hours before and 
after chemotherapy while 6 were to maintain a “healthy” diet. The 
content of the ad libitum diet was not given in detail but it was 
mentioned that patients were encouraged to eat at least 2 pieces of 
fruit per day. As one would expect, it was not feasible to conceal which 
of the 2 groups each patient belonged. Thus, subject blinding was not 
possible for this study.10  
 In order to assess the effect of STF during chemotherapy, serial 
blood samples were collected prior to and after TAC administration and 
analyzed for metabolic, endocrine, hematologic and inflammatory 
parameters. Damage to peripheral lymphocytes and monocytes was 
inferred via accumulation of phosphorylated serum H2AX, the presence 
of which has been implicated in the damage of healthy cellular 
material.11,12 After each cycle of chemotherapy, patients in both study 
and control groups provided a self-report of TAC associated side 
effects ranging from mild to severe via the Common Terminology 
Criteria for Adverse Events version 4.03.10 
 Statistical analysis of patient data determined no significant 
difference in self-reported side effects such as fatigue, diarrhea, 
dizziness, nausea, mucositis and etc.10 However, there was a 
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significant decrease in levels of phosphorylated H2AX in peripheral 
myeloid cells seen in the STF compared to the non-STF group 30 
minutes and up to 7 days after chemotherapy.This observation may 
suggest attenuation of DNA damage to peripheral blood 
mononucleated cells as a result of fasting during pharmacological 
management of breast cancer. Serum analysis also demonstrated a 
significant increase in erythrocyte and thrombocyte levels within the 
STF group.10  
  
Discussion  
Non-human preliminary studies5-8,13 have suggested a benefit of 
STF via molecular signaling pathways that involve insulin-like growth 
factor-I (IGF-I) and glucose. This research has demonstrated that 
fasting decreases circulating levels of IGF-I. This decrease in IGF-I 
leads to a shift of energetic resources in healthy, normally functioning 
cells to a state of relative quiescence while cancerous cells continue 
the processes of translation and division despite a condition which 
would normally temper growth.5,7,13 As such, it has been postulated 
that this unchecked cellular division in absence of sufficient fuel for 
aerobic respiration (glucose) leads to an accumulation of reactive 
oxygen species (ROS) and DNA damage which renders cancerous cells 
more susceptible to chemotherapeutic agents while selectively 
 15 
protecting healthy tissue.5-8 This phenomena is known as differential 
stress resistance (DSR).5-8 Both in-vitro and animal models5,7,8 have 
supported this proposed mechanism of fasting’s benefit.  If found to be 
safe and feasible to use in human patients, DSR could potentially be 
applied in oncological management regardless of cancer type.  
 The studies9,10 reviewed here directly address both safety and 
viability of STF during chemotherapy while also offering a nod to 
potential clinical benefit. Safdie and colleagues9 gathered self-reported 
side effects from 10 patients with a variety of different cancer 
diagnoses and varying chemotherapeutic treatments. This was not a 
clinical trial, as such, patients were not placed into a control group. 
However, patients did often act as their own control by utilizing STF 
during some (but not all) of their fasting cycles.9 All 10 patients who 
undertook STF reported a decrease in chemotherapy associated side 
effects (see Figure 1). Not only were side effects diminished, STF did 
not appear to hinder the benefit of chemotherapy as demonstrated by 
a reduction of cancer burden and/or endocrine markers such as CA-
125 and PSA.9 
However, it should be acknowledged that by nature of being a 
case report study, major limitations exist within this piece of research. 
Of particular note is the very small sample size, inability to blind 
patients to treatment type and lack of an established control group. 
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Yet, despite these limitations, the self-reported improvement in 
adverse symptoms associated with chemotherapy and apparent lack of 
detrimental consequence during STF bodes well for future clinical trials 
employing STF during chemotherapy.  
 More recently, de Groot et al10 were able to demonstrate a 
potential benefit of STF on hematologic parameters typically deranged 
through chemotherapeutic toxicity. As mentioned in the results section 
for this paper, the de Groot et al study10 was unable to glean a 
significant difference between the control and STF groups in regard to 
side effect profiles, absolute neutrophil and leukocyte counts or levels 
of IGF-I. In light of this, future research employing STF and 
chemotherapy may see an enhanced benefit of STF if dexamethasone 
is not given prophylactically and/or with an extension of STF beyond 
the 24 hours prior to and after chemotherapeutic treatment.  
 Although the self-reported side effect profile did not appear to be 
altered by STF, a significant improvement in certain hematologic 
parameters (ie, erythrocyte and thrombocyte count) as well as a 
decrease in a by-product of PBMC genetic damage was noted. Not only 
was this improvement discerned, it can also be stated that fasting for 
these patients (7 total with HER-2 negative breast cancer) was both 
safe and tolerable.10 
The most obvious limitations of this study are its small sample 
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size and attrition of 2 subjects from the STF group. Aside from its 
limited power, this trial has a number of other subtle yet potentially 
dramatic confounders. For example, both dexamethasone and 
pegfilgrastim (a granulocyte colony stimulating factor) were given to 
all patients while undergoing cycles of TAC.10 The use of these drugs 
may have led to alterations in metabolic and hematologic profiles, 
which could have obscured the potential benefit of STF. Finally, 
patients in the STF group undertook only 48 total hours of fasting 
whereas prior research9,13 has suggested that longer periods of fasting 
may be required for the metabolic benefit fasting may imbue. 
 
Conclusion 
The current studies that have employed STF as an adjunct to 
chemotherapy do not provide adequate evidence to suggest the 
judicious application of this method currently. Only randomized 
controlled trials with a sample size sufficient to offer substantial power 
could establish STF as a beneficial compliment to traditional cancer 
treatment modalities. However, the two studies reviewed here do 
imply that STF may be safe, feasible and perhaps even beneficial to 
study in future randomized controlled trials.    
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Table I: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of 
studies 
Study 
Designs 
Downgrade Criteria 
Quality  
 
 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
chemotoxic 
symptoms  
1 Case Series 
Report  
 
Not 
Serious 
 
Not Serious Not Serious Seriousa Unlikely Very 
Low 
Hematologic 
profile   
1 Randomized 
pilot study 
 
Seriousa Not Serious Not Serious Seriousa Unlikely Low 
a Small sample size 
bAttrition of 2 original participants 
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Figure 1. Self‐ reported side‐ effects after chemotherapy with or without fasting. Data 
represent average of CTCAE grade from matching fasting and non‐ fasting cycles (Ad Lib). 6 patients 
received either chemotherapy‐ alone or chemo‐ fasting treatments. Self‐ reported side effects from the 
closest two cycles were compared one another. Statistic analysis was performed only from matching 
cycles. Data presented as standard error of the mean (SEM). P value was calculated with unpaired, two 
tail t test. (*, P<0.05). 9 
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